BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1199 related articles for article (PubMed ID: 16990856)

  • 1. Topoisomerase I inhibitors: camptothecins and beyond.
    Pommier Y
    Nat Rev Cancer; 2006 Oct; 6(10):789-802. PubMed ID: 16990856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.
    Pommier Y
    Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):429-34. PubMed ID: 15379698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
    Tomicic MT; Kaina B
    Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular determinants of response to topoisomerase I inhibitors].
    Pourquier P; Lansiaux A
    Bull Cancer; 2011 Nov; 98(11):1287-98. PubMed ID: 22049384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of resistance to topoisomerase I-targeting drugs.
    Rasheed ZA; Rubin EH
    Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
    van Waardenburg RC; de Jong LA; van Eijndhoven MA; Verseyden C; Pluim D; Jansen LE; Bjornsti MA; Schellens JH
    J Biol Chem; 2004 Dec; 279(52):54502-9. PubMed ID: 15471886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
    Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
    Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
    Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
    Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors.
    Pommier Y; Jenkins J; Kohlhagen G; Leteurtre F
    Mutat Res; 1995 Sep; 337(2):135-45. PubMed ID: 7565862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
    Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
    Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
    Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
    Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.
    Hartmann JT; Lipp HP
    Drug Saf; 2006; 29(3):209-30. PubMed ID: 16524321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A symphony for the camptothecins].
    Lansiaux A; Bailly C
    Bull Cancer; 2003 Mar; 90(3):239-45. PubMed ID: 12801826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
    Garcia-Carbonero R; Supko JG
    Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Topoisomerase I in the Era of Precision Medicine.
    Thomas A; Pommier Y
    Clin Cancer Res; 2019 Nov; 25(22):6581-6589. PubMed ID: 31227499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
    Goldwasser F; Shimizu T; Jackman J; Hoki Y; O'Connor PM; Kohn KW; Pommier Y
    Cancer Res; 1996 Oct; 56(19):4430-7. PubMed ID: 8813137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
    Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R
    PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage.
    Adachi N; So S; Koyama H
    J Biol Chem; 2004 Sep; 279(36):37343-8. PubMed ID: 15218034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diversity of DNA topoisomerases I and inhibitors.
    Pommier Y
    Biochimie; 1998 Mar; 80(3):255-70. PubMed ID: 9615865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.